Travere Therapeutics, Inc. Common Stock
TVTX
$42.13
+37.23%
Travere Therapeutics is a biopharmaceutical company focused on developing and delivering therapies for rare kidney, liver, and metabolic diseases. The company is a specialized player in the orphan drug space, with its distinct identity built around its late-stage investigational product, sparsentan, for rare kidney disorders like FSGS and IgAN. The current investor narrative is dominated by the binary outcome of sparsentan's regulatory pathway and commercial potential, alongside the progress of its other pipeline asset, pegtibatinase, for HCU. Recent stock volatility reflects the market's ongoing assessment of clinical data, regulatory timelines, and the commercial ramp of its lead asset against a backdrop of high cash burn typical of development-stage biotech.…
TVTX
Travere Therapeutics, Inc. Common Stock
$42.13
Investment Opinion: Should I buy TVTX Today?
Rating: Hold. The thesis is that TVTX is a high-risk, binary biotech investment currently in a consolidation phase after a major rally; it is fairly valued for its speculative potential but requires successful execution to justify further upside, making it suitable only for risk-tolerant investors with a long time horizon.
Supporting evidence includes a forward P/E of 6.97x pricing in a sharp profit turnaround, a high gross margin of 85.51% providing a profitability foundation, and analyst revenue estimates implying massive growth to $1.52B. However, these are counterbalanced by high financial leverage (D/E 2.86), negative current profitability (ROE -43.77%), and a valuation (PS 6.95x) that already embeds significant success. The stock's position at 41% of its 52-week range suggests it is not overly extended, but the recent -16.25% 3-month decline indicates fading momentum.
The two biggest risks are commercial execution for sparsentan and the company's leveraged balance sheet. This Hold rating would upgrade to a Buy if the stock breaks down further toward stronger technical support near $25, offering a better margin of safety, or if Q1 commercial sales for sparsentan meaningfully exceed initial estimates. It would downgrade to a Sell if quarterly cash burn accelerates, debt covenants become a concern, or early prescription data points to slow uptake. Relative to its own risk profile and the binary nature of its pipeline, the stock appears fairly valued, neither egregiously overvalued nor compellingly cheap.
Sign up to view all
TVTX 12-Month Price Forecast
The outlook for TVTX is bifurcated, hinging entirely on the commercial execution of sparsentan over the next 12 months. The base case (50% probability) sees the stock trading sideways to slightly up as sales materialize, but this is balanced by a meaningful bear case (20%) driven by launch risks. The bull case (30%) offers substantial upside but requires flawless execution. The neutral stance reflects this balanced risk/reward at current levels. Confidence is medium due to the limited analyst coverage and binary nature of the catalyst. The stance would upgrade to bullish on confirmation of strong quarterly sales growth (>25% QoQ) and downgrade to bearish on any indication of slowing prescription trends or a need for emergency financing.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Travere Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $54.77 and implied upside of +30.0% versus the current price.
Average Target
$54.77
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$34 - $55
Analyst target range
Analyst coverage for TVTX is limited, with only 4 analysts providing estimates, which is typical for a small to mid-cap biotech stock and can lead to higher volatility and less efficient price discovery. The consensus sentiment must be inferred from estimates, as explicit Buy/Hold/Sell ratings and price targets are not provided in the dataset. The average revenue estimate for the forward period is $1.52 billion, with a wide range from a low of $1.27 billion to a high of $1.83 billion, indicating significant uncertainty in the commercial outlook. The average EPS estimate is $5.07, with a similarly broad range from $4.01 to $6.41. This wide dispersion in both revenue and EPS forecasts signals high uncertainty among analysts, likely centered on the uptake trajectory for sparsentan, pricing, competitive dynamics, and the timeline for pegtibatinase development. The high target likely assumes strong market adoption and favorable reimbursement, while the low target may factor in slower commercialization, market share challenges, or clinical setbacks.
Bulls vs Bears: TVTX Investment Factors
The evidence for TVTX presents a classic high-risk, high-reward biotech scenario, with the bear case currently holding a slight edge due to near-term financial and momentum pressures. Bull points are forward-looking, anchored in expected profitability (forward P/E 6.97x) and high-margin potential, while bear points highlight present realities of high leverage (D/E 2.86), cash burn, and recent underperformance (-16.25% over 3 months). The single most important tension in the investment debate is the market's valuation of future sparsentan sales (PS 6.95x) against the company's current precarious financial health and execution risk. The resolution of this tension—through either successful commercialization or a stumble—will dictate the stock's direction.
Bullish
- Strong Forward Profitability Expectations: The forward P/E of 6.97x, compared to a negative trailing P/E, indicates analysts expect a dramatic shift to profitability. This is underpinned by an average forward EPS estimate of $5.07, which would represent a massive earnings inflection if achieved.
- Robust Gross Margin Profile: The company's gross margin stands at a high 85.51%, indicating strong pricing power and a favorable cost structure for its potential therapies. This provides a solid foundation for future profitability once commercial scale is reached.
- Significant Revenue Upside Priced In: Analysts project average annual revenue of $1.52 billion, a figure not yet realized, suggesting the market is pricing in the successful launch and commercialization of sparsentan. The high estimate of $1.83 billion implies substantial upside if execution is strong.
- Attractive Technical Entry Point: The current price of $28.96 is near the 41st percentile of its 52-week range ($13.14-$42.13), representing a significant retreat from recent highs. This pullback, following a 114.68% 1-year gain, may offer a better risk/reward entry for the long-term trend.
Bearish
- High Financial Leverage and Burn: The company carries a high debt-to-equity ratio of 2.86 and is currently unprofitable with a -10.24% net margin and negative ROE of -43.77%. This creates dependency on external financing and increases risk if commercialization is delayed or underwhelming.
- Binary Dependency on Lead Asset: The investment thesis is overwhelmingly tied to the regulatory and commercial success of sparsentan. The wide dispersion in analyst revenue estimates ($1.27B to $1.83B) highlights the extreme uncertainty surrounding this single product's market uptake.
- Recent Momentum Breakdown: The stock has underperformed the SPY by -14.15% over the last three months, with a -16.25% price decline in that period. This signals a loss of momentum and potential trend reversal after the prior rally, raising near-term downside risk.
- Elevated Valuation on Unproven Sales: The stock trades at a trailing PS ratio of 6.95x and EV/Sales of 5.92x based on current, pre-commercial sales. This premium valuation leaves little room for error and is vulnerable to compression if revenue growth disappoints.
TVTX Technical Analysis
The stock is in a volatile, long-term uptrend but has recently entered a corrective phase. With a 1-year price change of +114.68%, the long-term trend is decisively bullish; however, the current price of $28.96 sits at approximately 41% of its 52-week range ($13.14 to $42.13), indicating a significant retreat from recent highs and positioning it closer to the lower bound, which may represent a value opportunity or signal a loss of momentum. Recent momentum shows clear divergence, with a 3-month price decline of -16.25% contrasting sharply with the strong 1-year performance, while the 1-month gain of +1.72% suggests a tentative attempt at stabilization after the sharp sell-off. This divergence signals a potential trend reversal or a deep consolidation phase following the prior rally, with the stock underperforming the SPY by -14.15% over the last three months. Key technical levels are clearly defined by the 52-week high of $42.13 and low of $13.14; a sustained break above the recent resistance near $32-$35 would signal a resumption of the uptrend, while a breakdown below the $26-$27 support zone could target the 52-week low. The stock's beta of 0.868 indicates it has been slightly less volatile than the broader market recently, but the high short ratio of 9.07 points to significant bearish sentiment and potential for sharp moves on positive news.
Beta
0.87
0.87x market volatility
Max Drawdown
-36.6%
Largest decline past year
52-Week Range
$14-$43
Price range past year
Annual Return
+184.1%
Cumulative gain past year
| Period | TVTX Return | S&P 500 |
|---|---|---|
| 1m | +51.5% | +4.9% |
| 3m | +45.6% | +0.6% |
| 6m | +53.1% | +5.1% |
| 1y | +184.1% | +28.8% |
| ytd | +6.6% | +1.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TVTX Fundamental Analysis
Revenue trajectory analysis is constrained as specific quarterly revenue and growth rate data are not available in the provided dataset. However, analyst estimates project average annual revenue of approximately $1.52 billion, suggesting the market anticipates significant future sales growth, likely tied to the potential launch and commercialization of sparsentan. The company is currently unprofitable, with a trailing net margin of -10.24% and an EPS of -$0.015, though a forward P/E of 6.97x implies analysts expect it to achieve profitability in the near future. Gross margin is robust at 85.51%, but this is offset by a negative operating margin of -12.80%, highlighting the high R&D and operational costs inherent in its clinical-stage business model. The balance sheet shows a leveraged but liquid position, with a high debt-to-equity ratio of 2.86, indicating significant financial leverage and risk. However, a strong current ratio of 2.74 suggests sufficient short-term liquidity to meet obligations. The deeply negative Return on Equity (ROE) of -43.77% and Return on Assets (ROA) of -6.55% reflect the company's current stage of investing heavily in its pipeline without generating commensurate earnings, underscoring its dependency on external financing and the critical need for successful product launches to improve financial health.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TVTX Overvalued?
Given the negative trailing net income and EPS, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 6.95x, while its Enterprise Value-to-Sales (EV/Sales) is 5.92x, providing a more capital-structure-neutral view of its sales multiple. The forward P/E of 6.97x, compared to a negative trailing P/E, underscores the market's expectation of a dramatic shift to profitability, likely priced on the anticipated success of sparsentan. Compared to industry averages, specific sector PS or EV/Sales multiples are not provided in the data, preventing a direct peer comparison. However, a PS ratio near 7x for a clinical/commercial-stage biotech is not uncommon and typically reflects a premium for high-growth potential in rare diseases, balanced against the binary risks of development and commercialization. Historical context for the stock's own valuation multiples is unavailable due to missing historical ratios data. Therefore, it is impossible to determine if the current PS ratio is near the top or bottom of its historical range, which limits the ability to assess whether the stock is priced for optimistic expectations or presents a value opportunity relative to its own trading history.
PE
-67.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
164.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced. The company operates with significant financial leverage (debt-to-equity of 2.86) and is burning cash, evidenced by a negative operating margin of -12.80% and deeply negative ROE of -43.77%. Revenue is entirely prospective, with analyst estimates averaging $1.52B, creating a binary dependency on the successful launch and rapid uptake of sparsentan. Any delay in regulatory approval, slower-than-expected market penetration, or pricing/reimbursement challenges would immediately threaten the company's ability to service its debt and fund operations, likely necessitating dilutive capital raises.
Market & Competitive Risks center on valuation compression and sector sentiment. Trading at a PS ratio of 6.95x on unproven sales, the stock carries a premium that is highly sensitive to growth expectations. A beta of 0.868 suggests slightly less volatility than the market, but this is misleading for a binary biotech; the stock's true risk is idiosyncratic. Competitive threats in the rare kidney disease space or negative clinical updates for its pipeline asset pegtibatinase could derail the growth narrative. Furthermore, the high short interest of 9.07 reflects a skeptical market that could amplify selling pressure on any negative news.
Worst-Case Scenario involves a combination of regulatory setbacks for sparsentan, disappointing early commercialization metrics, and a tightening financing environment. This could trigger a rapid de-rating as the path to profitability elongates. The realistic downside is significant, referencing the 52-week low of $13.14. From the current price of $28.96, a full reversion to that low represents a potential loss of approximately -55%. A more probable adverse scenario, incorporating some residual pipeline value, might see the stock fall to the $20-$25 range, representing a -14% to -31% decline from current levels.
FAQ
The key risks are, in order of severity: 1) Commercial/Execution Risk: The company's future is binary on sparsentan's launch success; disappointing sales would collapse the thesis. 2) Financial Risk: High debt-to-equity (2.86) and current cash burn (negative operating margin) create liquidity dependency. 3) Valuation Risk: The PS ratio of 6.95x leaves little room for error and could compress sharply. 4) Pipeline Risk: Setbacks for pegtibatinase would eliminate a key future growth driver. The high short interest (9.07 ratio) also indicates a skeptical market that can amplify negative news.
The 12-month forecast is highly scenario-dependent. The base case (50% probability) sees the stock trading between $30 and $35 as sparsentan sales materialize in line with average analyst estimates of $1.52B revenue. The bull case (30% probability) could drive the stock toward its 52-week high range of $38-$42 on strong sales execution and pipeline progress. The bear case (20% probability) could see a decline to $20-$25 on commercial disappointments and financing concerns. The most likely outcome is the base case, assuming a steady but not spectacular drug launch.
TVTX appears fairly valued relative to its high-risk profile. The primary metric is a Price-to-Sales ratio of 6.95x, which prices in substantial future sales growth that has not yet materialized. The forward P/E of 6.97x is low, but this is a projection based on expected earnings that are far from certain. Without direct peer comparisons, it's difficult to call it cheap or expensive absolutely. The valuation implies the market expects successful commercialization of sparsentan and a rapid path to profitability. Given the execution risk, this expectation seems fairly priced, not overly optimistic nor pessimistic.
TVTX is a high-risk, high-potential reward stock that may be a good buy only for a specific investor profile. For risk-tolerant investors with a long-term horizon who understand biotech binary events, the current price near the lower half of its 52-week range could be an entry point. The forward P/E of 6.97x suggests significant upside if profitability is achieved. However, it is not a good buy for conservative investors due to its high debt (D/E 2.86), current losses, and dependency on a single product launch. The key is a strong conviction in sparsentan's commercial success.
TVTX is strictly a long-term investment, with a suggested minimum holding period of 3-5 years. This timeframe is necessary to see through the commercial ramp of sparsentan, the achievement of profitability, and the progression of the pegtibatinase pipeline. The stock's beta of 0.868 understates its true volatility related to binary events. It pays no dividend and is not profitable, eliminating it as an income or short-term trade for most. Short-term trading is extremely risky due to high volatility around earnings and clinical updates. Only investors with a long-term view on the company's pipeline should consider it.